(Q38062793)

28 August 2017

1 reference

title

Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end? (English)

1 reference

28 August 2017

1 reference

Shota Tanaka

1

1 reference

28 August 2017

David N Louis

2

1 reference

28 August 2017

William T Curry

3

1 reference

28 August 2017

Tracy T Batchelor

4

1 reference

28 August 2017

Jorg Dietrich

5

1 reference

28 August 2017

language of work or name

English

0 references

publication date

27 November 2012

1 reference

Nature Reviews Clinical Oncology

28 August 2017

published in

1 reference

28 August 2017

volume

10

1 reference

28 August 2017

issue

1

1 reference

28 August 2017

page(s)

14-26

1 reference

Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

The 2007 WHO classification of tumours of the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

MGMT gene silencing and benefit from temozolomide in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

A hypermethylated phenotype is a better predictor of survival than MGMT methylation in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

IDH1 and IDH2 mutations in gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Targeting PI3K signalling in cancer: opportunities, challenges and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Targeting RAS signalling pathways in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

p53 in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Clonal expansion of p53 mutant cells is associated with brain tumour progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Genetic alterations and signaling pathways in the evolution of gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Antiangiogenic therapies for high-grade glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Mechanisms underlying PTEN regulation of vascular endothelial growth factor and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Angiogenesis in brain tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Notch signaling, gamma-secretase inhibitors, and cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Mechanisms of Disease: the role of stem cells in the biology and treatment of gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Glioma stem cell signaling: therapeutic opportunities and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Inhibition of notch signaling in glioblastoma targets cancer stem cells via an endothelial cell intermediate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Endothelial cells stimulate self-renewal and expand neurogenesis of neural stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

21 January 2018

Brain tumour stem cells

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Oligodendroglioma: toward molecular definitions in diagnostic neuro-oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Small cell architecture--a histological equivalent of EGFR amplification in glioblastoma multiforme?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Gone FISHing: clinical lessons learned in brain tumor molecular diagnostics over the last decade

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

A sensitive and specific diagnostic panel to distinguish diffuse astrocytoma from astrocytosis: chromosome 7 gain with mutant isocitrate dehydrogenase 1 and p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

In situ analysis of integrin and growth factor receptor signaling pathways in human glioblastomas suggests overlapping relationships with focal adhesion kinase activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Rapid radiographic and clinical improvement after treatment of a MET-amplified recurrent glioblastoma with a mesenchymal-epithelial transition inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Glioma stem cells promote radioresistance by preferential activation of the DNA damage response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Efficacy and safety of vismodegib in advanced basal-cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

American Society of Clinical Oncology 2010: report of selected studies from the CNS tumors section

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Phase II study of sunitinib malate in patients with recurrent high-grade glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Integrins in angiogenesis and lymphangiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Cancer immunoediting in malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Vaccines for glioblastoma and high-grade glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Monitoring of regulatory T cell frequencies and expression of CTLA-4 on T cells, before and after DC vaccination, can predict survival in GBM patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Pharmaco-economic aspects of sipuleucel-T.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Sequential immunotherapy by vaccination with GM-CSF-expressing glioma cells and CTLA-4 blockade effectively treats established murine intracranial tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Crosstalk between the PI3K/mTOR and MEK/ERK pathways involved in the maintenance of self-renewal and tumorigenicity of glioblastoma stem-like cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Circulating tumor cells, disease progression, and survival in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Methylated tumor-specific DNA as a plasma biomarker in patients with glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Neurological adverse effects caused by cytotoxic and targeted therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Response criteria for phase II studies of supratentorial malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: comparative analysis of the Macdonald, RECIST, RANO, and RECIST + F criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Radiographic patterns of relapse in glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Bevacizumab does not increase the risk of remote relapse in malignant glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Response criteria for glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Diffusion and diffusion tensor imaging in brain cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Reevaluating the imaging definition of tumor progression: perfusion MRI quantifies recurrent glioblastoma tumor fraction, pseudoprogression, and radiation necrosis to predict survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Functional diffusion maps (fDMs) evaluated before and after radiochemotherapy predict progression-free and overall survival in newly diagnosed glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Phase 2 trial design in neuro-oncology revisited: a report from the RANO group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

It is time to include patients with brain tumors in phase I trials in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Clinical trial end points for high-grade glioma: the evolving landscape.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Recurrent glioblastoma: a fresh look at current therapies and emerging novel approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

An integrated genomic analysis of human glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment [...]

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Mgmt methylation is a prognostic biomarker in elderly patients with newly diagnosed glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

DCVax-Brain and DC vaccines in the treatment of GBM

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.204

Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma

31 March 2020

1 reference

12 December 2020

Activation of p38 MAPK and/or JNK contributes to increased levels of VEGF secretion in human malignant glioma cells

1 reference

12 December 2020

Loss of wild-type p53 bestows a growth advantage on primary cortical astrocytes and facilitates their in vitro transformation.

1 reference

12 December 2020

Isocitrate dehydrogenase 1 analysis differentiates gangliogliomas from infiltrative gliomas

1 reference

12 December 2020

Clinicopathologic aspects of 1p/19q loss and the diagnosis of oligodendroglioma

1 reference

12 December 2020

Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations.

1 reference

12 December 2020

10.1038/NRCLINONC.2012.204

Identifiers

DOI

1 reference

28 August 2017

1 reference